Literature DB >> 33434072

Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors.

Natalie S Grover1,2, Nicholas Tschernia1,2, Gianpietro Dotti1,3, Barbara Savoldo1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33434072      PMCID： PMC8462586          DOI： 10.1200/JCO.20.01738

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  72 in total

1.  Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Authors:  Miriam Y Kim; Kyung-Rok Yu; Saad S Kenderian; Marco Ruella; Shirley Chen; Tae-Hoon Shin; Aisha A Aljanahi; Daniel Schreeder; Michael Klichinsky; Olga Shestova; Miroslaw S Kozlowski; Katherine D Cummins; Xinhe Shan; Maksim Shestov; Adam Bagg; Jennifer J D Morrissette; Palak Sekhri; Cicera R Lazzarotto; Katherine R Calvo; Douglas B Kuhns; Robert E Donahue; Gregory K Behbehani; Shengdar Q Tsai; Cynthia E Dunbar; Saar Gill
Journal:  Cell       Date:  2018-05-31       Impact factor: 41.582

2.  ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Authors:  Paolo Strati; Michelle A Fanale; Yasuhiro Oki; Francesco Turturro; Luis E Fayad; Nancy L Bartlett; Douglas E Gladstone; Yvette L Kasamon; Carol S Portlock; Wyndham H Wilson; Andre Goy; Anas Younes; Hun Ju Lee
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

3.  Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Authors:  Jianhong Chu; Shun He; Youcai Deng; Jianying Zhang; Yong Peng; Tiffany Hughes; Ling Yi; Chang-Hyuk Kwon; Qi-En Wang; Steven M Devine; Xiaoming He; Xue-Feng Bai; Craig C Hofmeister; Jianhua Yu
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

4.  An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.

Authors:  A Hombach; C Heuser; R Sircar; T Tillmann; V Diehl; C Pohl; H Abken
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

5.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 6.  Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.

Authors:  Joana M Murad; David J Graber; Charles L Sentman
Journal:  Best Pract Res Clin Haematol       Date:  2018-03-27       Impact factor: 3.020

Review 7.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

Authors:  R H Scheuermann; E Racila
Journal:  Leuk Lymphoma       Date:  1995-08

8.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Authors:  Marco Ruella; Jun Xu; David M Barrett; Joseph A Fraietta; Tyler J Reich; David E Ambrose; Michael Klichinsky; Olga Shestova; Prachi R Patel; Irina Kulikovskaya; Farzana Nazimuddin; Vijay G Bhoj; Elena J Orlando; Terry J Fry; Hans Bitter; Shannon L Maude; Bruce L Levine; Christopher L Nobles; Frederic D Bushman; Regina M Young; John Scholler; Saar I Gill; Carl H June; Stephan A Grupp; Simon F Lacey; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

9.  Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Authors:  Yawara Kawano; Shiho Fujiwara; Naoko Wada; Mikiko Izaki; Hiromichi Yuki; Yutaka Okuno; Kenichi Iyama; Hiroshi Yamasaki; Akira Sakai; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2012-07-04       Impact factor: 5.650

Review 10.  The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.